turoctocog alfa

DRUG18 trials

Conditions

Congenital Bleeding DisorderHaemophilia AHaemostasis

Phase 1

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2009-03-31End: 2009-10-31Updated: 2017-02-10

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

CompletedNCT01238367

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2010-11-30End: 2011-10-31Updated: 2017-02-10

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

CompletedNCT01365520

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2011-06-30End: 2011-09-30Updated: 2017-02-10

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

CompletedNCT01692925

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2012-12-31End: 2013-03-31Updated: 2017-02-10

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

CompletedNCT02941354

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2016-10-10End: 2017-06-20Updated: 2019-01-30

Phase 2

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

CompletedNCT03196297

Novo Nordisk A/SHaemophilia A, Haemostasis

Start: 2017-08-16End: 2020-06-03Updated: 2021-11-16

Phase 3

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

CompletedNCT00840086

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2009-04-30End: 2011-09-30Updated: 2017-03-17

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

CompletedNCT00984126

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2009-10-26End: 2016-06-29Updated: 2017-07-27

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

CompletedNCT01138501

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2010-06-30End: 2011-11-30Updated: 2017-03-17

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

CompletedNCT01493778

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2012-09-17End: 2018-12-05Updated: 2020-11-30

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

CompletedNCT02938585

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2016-12-12End: 2018-12-12Updated: 2020-07-27

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

TerminatedNCT03588741

Novo Nordisk A/SHaemophilia A

Start: 2018-06-12End: 2019-06-19Updated: 2020-07-07

Phase 4

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period

CompletedNCT03449342

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2018-03-01End: 2019-04-22Updated: 2020-04-17

Unknown Phase

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

CompletedNCT02035384

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2014-06-05End: 2020-01-15Updated: 2020-04-27

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

CompletedNCT02207218

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2014-08-04End: 2020-11-10Updated: 2021-11-15

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

CompletedNCT03179748

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2018-06-20End: 2021-06-16Updated: 2021-11-15

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

CompletedNCT04584892

Novo Nordisk A/SHaemophilia A

Start: 2021-04-12End: 2023-03-27Updated: 2023-11-28

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

CompletedNCT06574984

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A

Start: 2024-11-10End: 2025-11-04Updated: 2026-06-17

2025-02-20

Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.

2024-11-0611 citations

Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.

2024-05-019 citations

Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis

Haemophilia2022-06-0626 citations

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Blood Advances2022-03-1542 citations

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Blood2021-11-056 citations

Improvement in Health-Related Quality of Life Measures after Long-Term, Daily, Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A/B with and without Inhibitors: Results from the Main and Extension Parts of Phase 2 Clinical Trials

Blood2021-11-052 citations

The <i>in Vitro</i> Effect on Thrombin Generation of Adding rFVIII or rFIX to Hemophilia a or b Plasma in the Absence or Presence of Concizumab

Blood2020-11-041 citations

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Blood2019-11-131 citations

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Blood2019-11-131 citations

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

2019-11-0198 citations

turoctocog alfa

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Phase 4

Unknown Phase

Related Papers